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Drug-coated balloon therapy for diseased superficial femoral arteries remains controversial.
Despite its clinical relevance, only a few computational studies based on simplistic two-
dimensional models have been proposed to investigate this endovascular therapy to date.
This work addresses the aforementioned limitation by analyzing the drug transport and
kinetics occurring during drug-coated balloon deployment in a three-dimensional geometry.
Methods
An idealized three-dimensional model of a superficial femoral artery presenting with a cal-
cific plaque and treated with a drug-coated balloon was created to perform transient mass
transport simulations. To account for the transport of drug (i.e. paclitaxel) released by the
device, a diffusion-reaction equation was implemented by describing the drug bound to spe-
cific intracellular receptors through a non-linear, reversible reaction. The following features
concerning procedural aspects, pathologies and modelling assumptions were investigated:
(i) balloon application time (60–180 seconds); (ii) vessel wall composition (healthy vs. calci-
fied wall); (iii) sequential balloon application; and (iv) drug wash-out by the blood stream vs.
coating retention, modeled as exponential decay.
Results
The balloon inflation time impacted both the free and specifically-bound drug concentrations
in the vessel wall. The vessel wall composition highly affected the drug concentrations. In
particular, the specifically-bound drug concentration was four orders of magnitude lower in
the calcific compared with healthy vessel wall portions, primarily as a result of reduced drug
diffusion. The sequential application of two drug-coated balloons led to modest differences
(~15%) in drug concentration immediately after inflation, which became negligible within 10
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minutes. The retention of the balloon coating increased the drug concentration in the vessel
wall fourfold.
Conclusions
The overall findings suggest that paclitaxel kinetics may be affected not only by the geomet-
rical and compositional features of the vessel treated with the drug-coated balloon, but also
by balloon design characteristics and procedural aspects that should be carefully
considered.
1. Introduction
The number of individuals suffering from lower limb peripheral artery disease is increasing
globally. The incidence of the disease in people aged 25 years and over was reported to be
approximately 230 million in 2015, representing a notable increase compared with the esti-
mated 202 million people affected by the disease in 2010 [1]. The pathology is characterized by
the presence of atherosclerotic lesions that, by protruding into the arterial lumen, obstruct the
blood flow and impair the perfusion of the lower limb [2]. The superficial femoral artery
(SFA), the longest arterial vessel of the human body [3], is the location of around half of the
peripheral atherosclerotic lesions, due to its morphology and biomechanics [4, 5]. Given the
lower risk of complications and the lower level of invasiveness, a primary endovascular revas-
cularization is usually preferred to surgical bypass for most SFA lesions [6]. Despite the ability
of self-expandable stents to bear the dynamic load typical of the femoral arteries, the role of
these bare-metal devices has become a matter of great controversy because of the high rate of
failure due to restenosis (~30%) and stent fracture [7]. Thus, in recent years, drug-coated bal-
loons (DCBs) have emerged as an alternative to the conventional non-medicated angioplasty/
stenting treatment of atherosclerotic SFAs.
DCBs are capable of limiting excessive neointima proliferation, by combining the mechani-
cal action of the angioplasty inflation with the therapeutic action of the antiproliferative drug
released and transferred into the vessel wall during the intervention [8]. In particular, pacli-
taxel-eluting balloons have shown promising results, inducing a desirable biological effect,
namely the inhibition of cellular proliferation, without the use of permanent implants [9].
Whether by single or sequential balloon inflation, DCBs may enhance the outcome in the pri-
mary treatment of SFA restenosis, with lower risk as compared to surgical bypass [10]. Despite
the initial promising findings in the case of treatment of lower limb arteries, the safety of pacli-
taxel-based systems for the SFAs has been questioned, given the high rate of death at 2–5 years
following DCB [11]. Moreover, recurrent restenosis remains a persistent problem following
DCB use as compared to surgical bypass [12]. For these reasons, further investigations of the
DCB mode of action for the treatment of peripheral artery disease are warranted.
Computational modelling has long been recognized as an effective tool to investigate the
phenomena of drug transport and kinetics associated with drug-eluting endovascular devices
[13, 14]. Through the inclusion of a reaction term within the governing drug transport equa-
tions, computational models provide insights into paclitaxel uptake and release with a level of
detail difficult or impossible to replicate with in-vitro or in-vivo methods. Despite the useful-
ness of computational methodology to assess the safety and the performance of DCBs, to date
only a few studies have considered drug transport following release from DCBs [15–18] and
only one of these has focused on its application in SFAs. Furthermore, all of these studies are
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inherently limited by their consideration of a highly-simplified two-dimensional (2D) vessel
geometry.
The present work addresses the aforementioned limitation by computationally investigat-
ing the efficacy and mode of action of DCBs in a three-dimensional (3D) SFA geometry. In
detail, an idealized asymmetric 3D computational model of a diseased SFA treated with a DCB
is presented to investigate the impact on the paclitaxel transport and kinetics of the following
features: (i) DCB inflation time, which may vary according to the device under consideration
and the preferences of the vascular surgeon; (ii) vessel wall material properties; (iii) sequential
application of multiple DCBs and; (iv) drug wash-out by the blood stream as opposed to the
permanence of DCB coating adhered to the lumen wall.
2. Material and methods
2.1 Computational model of a diseased SFA treated with a DCB
An idealized 3D model of a diseased SFA treated with a paclitaxel coated balloon was created
using the computer aided-design modeler Rhinoceros 3D (v.6, Robert McNeel & Associates,
Seattle, WA, USA) (Fig 1), assuming a complete patency (100%) achieved during the balloon
Fig 1. A) Geometrical model of a 3D idealized portion of diseased superficial femoral artery (SFA), highlighting the computational grid employed within the wall at the
inlet cross-section (on the left) and cross-section of the diseased portion characterized by the presence of a calcific plaque (on the right). B) Section along the
longitudinal direction of the SFA model, with the definition of the computational domains and boundaries.OHEAL: healthy domain;OCALC: calcific plaque domain;
OBLOOD: lumen domain (not meshed); ΓLUMEN: lumen wall; ΓBALL: lumen wall in contact with the balloon; ΓOP: lateral openings of the vessel wall; ΓADV: adventitial wall.
https://doi.org/10.1371/journal.pone.0256783.g001
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inflation, resulting in a constant lumen diameter of 7.3 mm [4]. The vessel model was subdi-
vided in a central diseased portion, which was treated with the DCB, and two healthy portions
proximal and distal to the lesion. The diseased portion included a calcific plaque (OCALC),
causing a lumen area reduction of 40% prior to DCB inflation. In accordance with Glagov’s
phenomenon of vascular remodeling [19], the vessel wall presented an increased thickness in
the proximity of the atherosclerotic plaque. By considering a thickness of 1.6 mm for the
healthy portions (22% of the lumen diameter, as measured in human SFAs through the Dopp-
ler ultrasound technique [20]), the thickness of the diseased portion was set equal to 1.9 mm,
slightly larger (~18%) than that of the healthy portions. The properties of the calcific plaque
OCALC in terms of drug diffusivity (1.99�10
−7 mm2/s) and maximum density of drug binding
sites (1.3 mmol/L) were derived from existing literature [21]. The properties of the healthy tis-
sue OHEAL, obtained from studies on healthy arterial vessels [18, 22], were assumed to be
5.41�10−5 mm2/s for the drug diffusivity and 4.2 mmol/L for the maximum density of binding
sites.
To simplify the complex interaction between the inflated balloon and the vessel wall, the
action of the device was imposed as a boundary condition. According to the instruction for
use of the IN.PACT Admiral device (Medtronic, Dublin, Ireland), whose characteristics were
representatively employed in this work, a balloon of 7.0x40 mm was considered to match the
dimensions of the idealized SFA model.
To perform the mass transport simulations, the geometrical model of the vessel wall was
discretized through ICEM CFD (v.18.2, Ansys Inc., Canonsburg, PA, USA) into tetrahedral
elements (global minimum element size set to 0.4 mm and local minimum size set to 0.025
mm) and 20 layers of prismatic elements with a gradual smaller size close to the lumen wall
ΓBALL and ΓLUMEN (with an exponential growth rate of 1.1 and a total height of 0.05 mm). A
mesh independence analysis was conducted to choose the mesh size in terms of element size
and number of prismatic layers. This analysis was based on the validation of the computational
model against the analytical solution of the transient linear diffusion equation in an idealized
hollow cylinder (detailed in the S1 File, Section “Analytical validation and sensitivity analy-
sis”), resulting in a final mesh cardinality of ~23 million elements. The blood domain was not
included in the analysis and, hence, it was not discretized. Our justification for this is based on
the fact that during balloon inflation the blood stream is impeded by the presence of the device
itself. Once the device is deflated and removed, blood wash-out may be modeled through the
prescription of a boundary condition on the lumen side of the wall, without increasing the
computational effort, as described in detail in section 2.2.2.
2.2 Computational analysis
2.2.1 Transport equations. To describe the transport of paclitaxel within the arterial tis-
sue, a transient diffusion-reaction model was defined in accordance with previous studies [18,
23]. In the absence of realistic values of the pressure gradient induced by DCB inflation across
the vessel wall, the contribution of advection to drug transport within the wall was neglected.
The interaction of paclitaxel with the components of the vessel wall was modelled as a non-lin-
ear, saturable, reversible reaction term [24]. In detail, the reversible binding of ligands (i.e. the
free paclitaxel molecules) with receptors (i.e. the specific intracellular receptors, corresponding
to the microtubules [25]) leading to the formation of a ligand-receptor complex was described.
This biological process, being reversible, is governed by the association and dissociation rate
constants, which are related to tissue properties. Fig 2 shows a schematic representation of the
biological processes and current understanding of the action of paclitaxel. Only the reversible
and saturable specific binding was integrated in this model, neglecting the non-specific
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binding of paclitaxel (namely the binding of the paclitaxel molecule to various extracellular
matrix components [15]). This is biologically translated into the exertion of the effect (i.e. inhi-
bition of the cellular proliferation or migration) by the specific intracellular receptors, which
leads to the arrest of the cellular mitosis (as schematically represented in Fig 2). Moreover, the
extracellular and intracellular free drug concentrations were assumed to be equal at all times,
an approximation that is valid when the transport across the cell membrane is sufficiently fast.
Therefore, the overall mathematical model of paclitaxel kinetics in the SFA wall was described
through the following system of equations:
@CF
@t

















Fig 2. Schematic representation of the biological process occurring during the cell cycle and the current understanding of the action of paclitaxel. After the phase
of growth and initial metabolic activity, the cell undergoes the phase of DNA replication and ulterior growth. Once maturity has been reached, the cell prepares for the
mitotic process, which in physiological conditions would lead to cell division into two identical daughter cells. However, when the system is subjected to the anti-
proliferative paclitaxel, the cell cycle is interrupted in the mitotic phase. The specific binding of paclitaxel molecules (CSB) to the intracellular microtubules determines
their stabilization and impedes their reorganization essential for the cellular division. Part of the paclitaxel exchanged from the extracellular (CF) to the intracellular
ambient (Ci) may remain unbound.
https://doi.org/10.1371/journal.pone.0256783.g002
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where CF and Ci represent the extracellular and intracellular concentration of the free pacli-
taxel (i.e. not bound to receptors), respectively; Deff is the effective diffusion coefficient (which
varies between the healthy and calcified vessel portions); CSB is the concentration of the specifi-
cally-bound drug; kon and kD are the association and dissociation rate constants, respectively
and; bmax is the maximum concentration of binding sites (i.e. active receptors available to
uptake paclitaxel, assumed to vary between the healthy and calcified portions) [26]. Summariz-
ing, the paclitaxel kinetics were described as a function of the free (CF) and the specifically-
bound drug concentrations (CSB). Table 1 summarizes the parameters of the mass transport
model, with the related values.
2.2.2 Boundary conditions. With reference to Fig 1B, the lumen wall in contact and not
in contact with the DCB were denoted ΓBALL and ΓLUMEN, respectively, the adventitial wall was
denoted ΓADV, and the lateral opening of the vessel was denoted ΓOP. Following a previous
work [28], a zero-flux condition was applied to ΓOP: due to the large distance from the region of
interest, this choice of boundary condition had negligible impact on the results. A perfect sink
condition was applied to ΓADV [18]. As a first approximation, the drug was not allowed to enter
the ΓLUMEN, and thus a zero-flux condition was applied. While all the other boundary condi-
tions were kept constant, at the beginning of the DCB inflation the drug concentration on
ΓBALL was set equal to the value of the initial concentration present on the DCB surface, assum-
ing a large excess of paclitaxel (3.5 μg/mm2, as declared in the instruction for use of IN.PACT
Admiral device). After DCB application, to mimic the removal of the balloon and the wash-out
of the blood, the drug concentration on ΓBALL was set to 0. In an attempt to understand the
impact of coating retention on the lumen wall, we also considered the case of an exponential
decay of drug concentration on ΓBALL [29] after removal of the balloon. The exponential decay,
defined as a negative, concentration-dependent flux, included a rate constant k (Table 1), which
was derived from previous experimental considerations [30]. In particular, it was assumed that
more than half of the coating load was lost in the first 20 minutes after balloon deflation.
2.2.3 Numerical solver. The mathematical model described in the system of Eq (1) was
solved using the commercial software CFX (v.18.2, Ansys Inc., Canonsburg, PA, USA). The
solver settings are summarized in Table 2.
2.3 Investigated scenarios
Based on the guidelines of the IN.PACT Admiral DCB, which suggests a balloon dilatation
time of 180 seconds for obtaining an optimum mechanical dilatation and a minimum time for
Table 1. List of the parameters of the drug transport model.
Parameter Ref. Value Description
Deff, H [22] 5.41�10−5 mm2/s Effective diffusion coefficient in the healthy wall
Deff, C [21] 1.99�10−7 mm2/s Effective diffusion coefficient in the diseased wall
C0
� 3.5 μg/mm2 Surface concentration of paclitaxel for the IN.PACT Admiral balloon
bmax,H [18] 4.2 mmol/L Maximum density of the binding sites in the healthy wall
bmax,C [21] 1.3 mmol/L Maximum density of the binding sites in the diseased wall
kD [25] 5�10−6 mmol/m3 Specific equilibrium dissociation constant
kon [27] 8�1011 mm3 /
(mol s)
Specific drug binding rate constant
k �� 6.5�10−7 kg / (m2
s)
Rate constant to define an exponential decay of drug concentration on the
lumen wall in contact with the balloon
� IN.PACTTM AdmiralTM drug coated balloon (Medtronic) instruction for use
�� Estimated from experimental considerations [30].
https://doi.org/10.1371/journal.pone.0256783.t001
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adequate drug transfer of 60 seconds, different clinical scenarios were considered for this
study. In detail, the effect on drug uptake and distribution was investigated when:
i. DCB inflation time was varied (i.e. 60, 120 and 180 seconds), for a single DCB application;
ii. sequential application of two DCBs was considered. An inflation time of 60 seconds was
simulated for the first DCB, followed by a clinically realistic interlude of 5 minutes before a
further inflation of a second fully loaded DCB for a time of 60 seconds. This double DCB
application (total inflation time of 60+60 seconds) was compared to the corresponding sin-
gle DCB application of 120 seconds;
iii. the coating was assumed to be retained on the lumen wall for a period of time after infla-
tion. The results of a single DCB application with 60-, 120- and 180-second inflation time
performed with the presence of the coating (i.e. exponential decay applied on ΓBALL) were
compared to the analyses with an efficient blood wash-out (i.e. null concentration applied
on ΓBALL).
2.4 Analysis of the results
For each investigated scenario, the free (CF) and the specifically-bound (CSB) drug concentra-
tions were compared immediately after DCB inflation (60, 120 or 180 seconds) and then sub-
sequently 10 minutes and 1 hour later. The temporal profiles of CF and CSB were analyzed
across the wall thickness in the healthy OHEAL and the calcific OCALC regions of the diseased
vessel wall. To simplify the comparison, the drug concentrations were normalized by the maxi-
mum concentration value (relative to OHEAL), for both CF and CSB concentrations. The free
drug was maximal during the balloon inflation in the proximity of ΓBALL. Thus, CF was nor-
malized by that value. On the contrary, CSB was normalized by the final value of the longest
DCB exposure (i.e. 180 seconds) observed at 1 hour after the DCB deflation.
3. Results
3.1 Impact of DCB inflation time
Fig 3 shows contour maps of the normalized specifically-bound (CSB) drug concentrations, fol-
lowing the 180-second exposure-time. The drug concentration was captured in 2D on both
the diseased and healthy portions of the lumen wall along the main vessel direction at 4 time
instants: the beginning and end of the DCB inflation (t0 and tEND), at 10 minutes and 1 hour
after DCB deflation. It is qualitatively observable that, due to the lower diffusivity of drug in
the calcific regionOCALC, drug penetration was limited inOCALC as compared toOHEAL. More-
over, the drug concentrations at 10 minutes and 1 hour after DCB deflation were almost
Table 2. List of the solver settings.
Type ANSYS CFX–pressure-based
Pressure-velocity coupling method Coupled
Spatial discretization scheme–gradient Least squares cell based
Spatial discretization scheme–pressure Second order
Spatial discretization scheme–momentum Second order upwind
Transient scheme Second order Backward Euler
Convergence control (max coefficient loops) 5
Convergence criterion for the global residuals 10−6
Time-step size 10 seconds
https://doi.org/10.1371/journal.pone.0256783.t002
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identical, highlighting the strong retention of the drug in the tissue. The penetration front of
CSB progressively moved towards the adventitia, following the free drug (CF) distribution (not
shown).
To gain a more quantitative insight, spatial profiles of CF and CSB along a line extending
from the lumen to the adventitia are shown for the three different inflations times for both the
healthy (Fig 4) and calcific tissues (Fig 5). Results are shown immediately after DCB inflation
and 10 minutes after DCB deflation. Considering firstly the comparison at the end of the DCB
inflation, the drug penetration front for the longest exposure (180 seconds) reached approxi-
mately 100 μm in the healthy portion (Fig 4), while in the calcific region the drug penetrated
only 50 μm (Fig 5), due to the lower diffusivity exhibited in OCALC. Focusing on OHEAL, differ-
ences up to ~30% in CF were observed between the 60- and 180-second exposures (Fig 4A).
Considering CSB, the largest difference between 60-second and longest 180-second DCB infla-
tions was visible in proximity of the lumen wall, where the free concentration was maximal
(Fig 4B). Despite the non-linearity of the specific binding kinetics, the maximal CSB value for
an inflation time of 180 seconds was almost three-fold the corresponding value for a 60-second
inflation.
The maximum value of CF observed for the 180-second exposure was approximately 4
orders of magnitude lower in OCALC (Fig 5A) compared with OHEAL (Fig 4A). Analogous find-
ings emerged for the bound drug (Figs 4B and 5B). Moreover, the reduction in the maximal
value of bound drug with decreasing inflation time in OCALC was non-linear, possibly
explained by the 3 orders of magnitude lower binding site density compared with the healthy
tissue.
Fig 3. Spatial maps of normalized specifically-bound (CSB) drug concentration on the section along the main direction in the case of DCB inflation of 180
seconds. The temporal evolution is studied at 4 time instants: the beginning (t0) and end (tEND) of the DCB inflation, at 10 minutes (10 min) and 1 hour (1h) after DCB
deflation. The location of the color maps is indicated at the top of the schematic.
https://doi.org/10.1371/journal.pone.0256783.g003
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Analyzing the drug concentration profile at 10 minutes after the DCB application, a
significant reduction of the free drug was observed in both OHEAL and OCALC particularly
near the lumen wall where blood wash-out conditions were imposed (on ΓBALL) (Figs 4A
and 5A). By this time, the drug had penetrated the full wall thickness in OHEAL (Fig 4A),
while the penetration distance inOCALC remained limited to 50 μm, owing to the presence of
the calcification (Fig 5A). At the lumen wall, due to the fast binding of paclitaxel, CBS was max-
imum for the case with 180-second exposure (Figs 4B and 5B). However, in the wall tissue far
from the lumen wall, the CBS penetration distance more than trebled in 10 minutes as a conse-
quence of increased CF penetration (Fig 4B). The diffusion-limited behavior of paclitaxel
kinetics can be better observed in the calcific portion where the distribution of CBS (whose
concentration increase 5-fold in 10 minutes, Fig 5B) declined rapidly, as with the free drug
concentration.
At 1 hour after DCB application, the free drug concentrations CF were negligible in the ves-
sel wall (results not shown). Furthermore, negligible differences (lower than 0.3%) in terms of
CSB emerged between the 10-minute and 1-hour distributions (Fig 3). This was a consequence
of the rapid withdrawal of the free drug by the blood wash-out, which limited the amount of
free drug that could subsequently be uptaken into the intracellular region and made available
for binding to the microtubule receptors.
Fig 4. Impact of DCB inflation time on normalized free CF (A) and bound CSB (B) drug concentrations along the vessel wall thickness in healthy regionsOHEAL. Results
are displayed for inflation times of 60, 120 and 180 seconds. The location of the profile analyzed is indicated on the cross-section.
https://doi.org/10.1371/journal.pone.0256783.g004
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Given the negligible drug concentrations in the OCALC, in the following sections the results
are shown for the OHEAL region only. Instead, the results for the OCALC are reported in the S1
File (Section “Supplementary results”) for the sake of completeness.
3.2 Impact of single vs. double DCB application
Fig 6 depicts the spatial profiles of the normalized free CF and bound CSB drug concentrations
in the healthy OHEAL regions of the treated portion of the lumen wall, comparing the single
with the sequential double DCB application (with the same total exposure time of 120 sec-
onds). As expected, CF and CSB displayed similar distributions in OHEAL between the single
and double DCB applications. Comparing the results at the end of the procedure (Fig 6, left
column), the values of CF were lower in the double DCB application compared with the single
application, with a maximum percentage difference of ~15% at a depth of 0.035 mm from the
lumen wall (Fig 6A). This follows from the shorter (60 seconds) application of the second load-
ing, which took place after the interlude of 5 minutes, interval long enough to consent a com-
plete removal of the free drug in the tissue. Since the single application presented a continuous
exposure for a longer time (120 seconds), at the end of the procedure CF resulted higher in the
tissue (Fig 5A). The values of CSB were lower (~38%) in the proximity of the lumen wall in case
of the double DCB application, due to the loss of free drug during the “interlude” between the
two inflations (Fig 6B). This effect was caused by the rapid blood wash-out that limited the
Fig 5. Impact of the DCB inflation time on normalized free CF (A) and bound CSB (B) drug concentrations along the vessel wall thickness in the calcific regionsOCALC.
Results are displayed for inflation times of 60, 120 and 180 seconds. The location of the profile analyzed is indicated on the cross-section.
https://doi.org/10.1371/journal.pone.0256783.g005
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quantity of drug available for the specific binding. However, moving towards the adventitia
(e.g. at a depth of 0.040 mm from the lumen wall), CSB was ~12% higher in the double DCB
application case, suggesting that the interlude phase promoted increased binding in the inter-
nal tissue (Fig 6B).
Concerning the results at 10 minutes after DCB application (Fig 6, right column), the differ-
ences in terms of free and bound drug were negligible between the two scenarios, because of a
larger availability of CF initially present after the longer single DCB application (Fig 6A). For
this reason, CSB was also comparable between the two scenarios, even if slightly larger in case
of the double DCB application (maximum difference < 5%, Fig 6B).
3.3 Impact of DCB coating retention
Fig 7 illustrates the spatial profiles of CF and CSB drug concentrations following inflations of 60
(Fig 7A), 120 (Fig 7B) and 180 (Fig 7C) seconds, examined at 10 minutes and 1 hour after
DCB application. From the comparisons performed between the coating retention and blood
wash-out cases, it emerged that the drug kinetics were not affected during the DCB inflation
and the spatial profiles of CF and CSB at the end of DCB application were identical (not
shown). The impact of coating retention is evident beginning from the comparison at 10 min-
utes. Indeed, in the case of coating retention, CF lost ~80% of the initial load in the proximity
Fig 6. Results of the sequential application of multiple DCBs. Profiles along the wall thickness immediately after and 10 minutes after DCB application. Plots display
(A) free (CF) and (B) specifically-bound (CSB) drug concentrations for the healthy region for the single (green line) and double (orange line) DCB applications. CF was
normalized by the initial values (initial drug loading, 3.5 μg/mm2); CSB was normalized by the maximum measured values, namely at 1 hour from the DCB removal.
https://doi.org/10.1371/journal.pone.0256783.g006
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of the lumen wall (for the 60 second exposure) but was still 3.5-fold larger than in case of effi-
cient blood wash-out (Fig 7A). As established in Section 3.1, the longer the initial DCB infla-
tion, the larger the amount of free drug remaining in the tissue, though the 3.5-fold difference
was maintained between the coating retention and wash-out cases.
The retention of the coating also induced notable differences in the profiles of CSB along the
wall thickness. In fact, with the coating retention the maximum concentration of CSB following
the 60-second inflation evaluated at 10 minutes reached the values observed in case of efficient
blood wash-out evaluated at 1 hour after the 180-second DCB application (see Fig 7A and Sec-
tion 3.1). Coherently, the maximal value of CSB at 1 hour was 10-fold higher assuming coating
retention compared with the assumption of blood wash-out. Similar trends were observed in
the cases of 120- and 180-second exposure time (Fig 7B and 7C, respectively). As previously
observed (Section 3.1), the longer the DCB inflation, the higher the observed bound drug con-
centrations in the tissue. However, the maximum differences of ~6% between the 60- and
Fig 7. Simulations of DCB inflation for (A) 60, (B) 120, and (C) 180 seconds in case of efficient blood wash-out (red) and coating retention (blue). The spatial profiles
of the free CF and bound CSB drug concentrations are compared at 10 minutes (continuous line) and at 1 hour (dotted line) after DCB application. Both CF and bound
CSB were normalized by their relative maximum values. CF was normalized by the initial values (initial drug loading); CSB was normalized by the maximum measured
values, namely at 1 hour after the DCB removal. When not visible, the red dotted line is overlapped to red solid line.
https://doi.org/10.1371/journal.pone.0256783.g007
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180-second exposure cases found on the lumen wall were negligible as compared to the varia-
tions introduced by the coating (Fig 7A and 7C). Indeed, the retention of the coating, even if
rapidly decaying in time, increased the retention of paclitaxel, and, consequently, the quantity
of CF available for specific binding. For this reason, despite 85% of the drug coating being lost
by 1 hour, CSB still increased up to 4-fold (in the case of 180-second exposure time, Fig 7C)
compared to the efficient blood wash-out scenario.
4. Discussion
In this computational study, a 3D mass transport model was proposed to describe drug deliv-
ery from a paclitaxel DCB for the treatment of diseased SFAs. Several features were investi-
gated including the impact of different procedural aspects (inflation time, multiple DCB
application), pathologies (healthy vs. calcified wall) and modelling assumptions (drug wash-
out by the blood stream vs. coating retention). The key findings of the work can be summa-
rized as follows: (i) the DCB inflation time impacts not only the free drug concentrations in
the arterial wall, but most importantly the amount of specifically-bound drug; (ii) specific
binding of paclitaxel is greatly reduced in calcific plaques, as compared to healthy portions of
the wall, primarily as a result of significantly reduced drug diffusion; (iii) a sequential applica-
tion of two fully-loaded DCBs leads to modest differences in drug concentration in the inner
part of the wall immediately after inflation, but the differences rapidly become negligible
(within 10 minutes); and (iv) retention of the DCB coating may lead to notable variation of the
drug free and specifically-bound drug concentrations in the vessel wall.
In contrast to the vast literature considering computational modeling of the drug eluting
stents (e.g. [28, 31–33]), where drug delivery is typically sustained over a period of weeks, the
number of published studies considering computational modeling of DCBs (and specifically
for diseased SFAs) is extremely low [15–18]. Given the limited time of contact between the
DCB external surface and the arterial wall, an adequate understanding of drug transport and
retention in a realistic arterial model and of the impact of procedural aspects becomes of
extreme importance for the success of DCB treatment for diseased SFAs [34].
The main methodological novelty of this work is the extension of the mass transport model
to the 3D setting, allowing the drug kinetics to be assessed in more realistic asymmetrical geo-
metrical configurations. The results are particularly interesting for the analysis of the treatment
of vascular segments characterized by lesions of unique composition and extent. Furthermore,
compared to other anatomical locations, DCB inflation in SFAs may be prolonged for several
minutes [35]. In accordance with the recent findings for 2D cross-sectional diseased coronary
arteries [15], the longer the DCB application, the deeper the penetration front within the tis-
sue. Moreover, the introduction of the behavior of the paclitaxel within the intracellular envi-
ronment through specific binding provides interesting insights coherent with previous
experimental findings [36], in which paclitaxel retention remained particularly high in the first
hour after DCB implantation.
From the findings on the impact of different tissue composition on drug transport, and in
accordance with previous literature on DCB computational modelling [15, 16, 18], marked dif-
ferences in terms of free and bound concentrations were found between the regions OHEAL
and OCALC. These results reflected the difference in terms of effective drug diffusivity, which
was 4 orders of magnitude lower in the diseased region than in the healthy one, and the lower
maximum binding sites density [21]. In particular, even after a 180-second DCB inflation,
which is suggested on the device instructions for use, the free drug concentrations in the cal-
cific region were 1000-fold lower than in the healthy tissue. Consequently, the diffusion-lim-
ited nature of paclitaxel transport [26] dictates that CSB in OCALC was also significantly
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reduced (approximately 4 order of magnitudes lower as compared to healthy regions). These
findings suggest that the mode of action of a DCB, besides the simplicity of the implantation
technique as compared to other treatments, might not be trivial. Specifically, in terms of the
drug concentrations that may be achieved in the vessel wall, our results indicate that this device
may well be highly-effective in healthy vessel tissue, yet possibly ineffective in calcified arteries
which are the ones that usually require intervention.
In the current clinical practice, a single DCB application is usually performed. However, to
avoid recurrent restenosis, multiple DCB applications may also be performed [10]. From this
analysis (in this specific case, a double DCB application), it has been demonstrated that the
paclitaxel kinetics are largely unaffected by the interventional procedure. In particular, similar
but not identical dynamics in terms of free and specifically-bound paclitaxel were found when
comparing the single with the double DCB application with the same total exposure time of
120 seconds.
Lastly, the drug kinetics in presence of an efficient blood wash-out (null concentration
applied on ΓBALL) was compared to the case of the DCB coating adhered to the lumen wall and
subjected to an exponential decay (exponential decay applied on ΓBALL). Notably, this analysis
illustrated that, considering the same inflation time, the retention of the coating on the vessel
wall widely affected the specifically-bound drug, trebling or even quadrupling its concentra-
tion within the arterial tissue as compared to the blood wash out condition. This result is in
agreement with recent experimental studies and suggests that more sophisticated modelling of
coating retention should be considered in future [29, 30].
The findings of this work have a general validity, as an idealized model was created compar-
ing different scenarios by changing one feature at a time while maintaining all the other char-
acteristics. The model developed here is characterized by a wide versatility that, for example,
could also allow replacement of the idealized geometry with a patient-specific geometrical
model (e.g. reconstructed from clinical images as previously performed on 2D sections [16]),
with the final aim of exploring personalized DCB applications. Furthermore, this 3D setting
also enables the integration of structural simulations of DCB application, which may provide
realistic values of the pressure gradient across the vessel wall to facilitate the realistic incorpo-
ration of interstitial flow. Perhaps more importantly, the state of deformation of the wall tissue
could also be introduced, information that could be, in principle, compared with observed in-
vivo application through imaging techniques. To date, in the available computational DCB lit-
erature, only the pressure gradient has been introduced (e.g. [15]), without the introduction of
the state of deformation induced in the arterial wall during the DCB application.
Finally, we wish to reiterate that although this work has produced interesting results, these
have to be considered within the context with the limitations of the model. Firstly, the idealized
model adopted in this work presents a single wall layer with homogeneous properties and pre-
senting with only two materials (i.e. healthy tissue and a calcific plaque). As recently studied in
a 2D mass transfer model of a stented coronary artery by Escuer et al. [28], different material
properties could be added to describe the intimal, medial and adventitial layers separately, as
well as the membranes at their interface. However, each additional component must be char-
acterized by diffusive and binding properties, whose values are not readily available in the liter-
ature in the case of SFAs, especially for patient-specific cases. With the ultimate goal of
investigating patient-specific cases, the introduction of an excessive level of detail would lead
to an overcomplication of the computational model, impeding a reliable though simpler analy-
sis of the major features influencing the drug kinetics. Moreover, although diffusion is com-
monly assumed to be the dominant mechanism during drug release and uptake [18, 23], the
porous nature of the vessel wall and the pressure gradient across the wall imposed during
angioplasty may contribute to a non-negligible advective term [15]. Hence, to further improve
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this mathematical model, which accounts only for the diffusion and reaction terms, the advec-
tion term could be incorporated. However, in a real clinical case scenario, this term should
reflect not only the pressure gradient induced during the angioplasty procedure, but also the
changes in the arterial morphology and thus the geometrical model. Lastly, the wash-out of the
DCB coating was described here through a simplistic exponential decay. However, this aspect
of the DCB mode of action should be more deeply analyzed. In particular, given the very recent
findings regarding DCB excipient technologies [9, 29], the different releasing mechanisms
from various coating microstructures (e.g. needle-shaped or spherical particles) of the DCB
could be implemented in a more sophisticated model.
5. Conclusions
This work presented a 3D computational mass transport model to investigate the mode of
action of paclitaxel DCB therapy in diseased SFA. Despite some simplifications, the present
work is the first study, to the best of authors’ knowledge, to investigate within a 3D setting, the
impact of sequential DCB application as well as of coating retention on diseased SFAs. The
findings suggested that the kinetics and thus the biological effects exerted by paclitaxel may be
affected not only by the geometrical and compositional features of the treated vessel, but also
by the balloon design characteristics and interventional procedural aspects that should be care-
fully considered. The proposed model is versatile and could ultimately be adapted to patient-
specific geometries accounting for different vessel wall layers and plaque components.
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